

## MEDIA RELEASE

# **Azure Health Technology Limited's nutraceutical products listed on Australia's Therapeutic Goods Administration's (TGA's) Australian Register of Therapeutic Goods (ARTG) as Listed Complementary Medicines**

**Sydney, Australia 18 January 2020** – Azure Health Technology Limited (AZT), the Company commercialising an innovative non-invasive and direct drug and vitamin delivery platform, is pleased to announce that its two nutraceutical products, NE1-Elite® and NE1-Heart®, are now listed on Australia's Therapeutic Goods Administration's (TGA's) Australian Register of Therapeutic Goods (ARTG) as Listed Complementary Medicines.

NE1-Elite® (AustL 351934) and NE1-Heart® (AustL 341935) both contain as the key dietary ingredient delta tocotrienols delivered by AZT's MELT3® (Melt then Swallow) platform. NE1-Elite® is clinically proven to reduce muscle soreness, assist in post-exercise recovery and improve muscle recovery time. NE1-Heart® reduces free radicals formed in the body and maintains a healthy heart function.

The listing of these two products as Listed Complementary Medicines on the ARTG allow the products to be sold in Australia providing that they are manufactured by current Good Manufacturing Practice (cGMP) manufacturers who are certified by the TGA. AZT has a long-standing engagement with one such cGMP contract manufacturer in the US.

The President and CEO of AZT's US subsidiary, Invictus Nutraceuticals, Inc., Richard Estalella said "While our initial focus was launching these two products in the US, the overwhelmingly positive response that we have had from Australian consumers, and in particular, sportspeople trying out the samples of NE1-Elite® made a totally compelling case for us to make sure that Australian customers can easily access these products. The listing of the products on the TGA's ARTG is a necessary step in bringing these products to Australian consumers".

The two products will initially be made available outside of the US through an online platform proprietary to a partner of AZT, Sydney-based AHP Group Ltd, which will allow consumers to order the products directly. AZT expects that by the H2 2021, these products will be available both online (direct to consumer through AHP Group Ltd) and through retail outlets in Australia.

For more information please contact:

Dr Glenn Tong  
CEO and Managing Director  
Tel: +61 (0) 412 193 350

Ms Catriona Glover  
Company Secretary  
Tel: +61 (0) 402 328 200

---

### **About Azure Health Technology Limited**

Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: <https://www.azureht.com.au/>